- Home
- CRVL vs LEGN Comparison
CRVL vs LEGN Comparison
Compare CRVL & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVL
- LEGN
- Stock Information
- Founded
- CRVL 1987
- LEGN 2014
- Country
- CRVL United States
- LEGN United States
- Employees
- CRVL N/A
- LEGN N/A
- Industry
- CRVL Specialty Insurers
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CRVL Finance
- LEGN Health Care
- Exchange
- CRVL Nasdaq
- LEGN Nasdaq
- Market Cap
- CRVL 4.6B
- LEGN 5.4B
- IPO Year
- CRVL 1991
- LEGN 2020
- Fundamental
- Price
- CRVL $87.64
- LEGN $38.42
- Analyst Decision
- CRVL
- LEGN Strong Buy
- Analyst Count
- CRVL 0
- LEGN 11
- Target Price
- CRVL N/A
- LEGN $74.60
- AVG Volume (30 Days)
- CRVL 161.6K
- LEGN 1.3M
- Earning Date
- CRVL 08-05-2025
- LEGN 08-11-2025
- Dividend Yield
- CRVL N/A
- LEGN N/A
- EPS Growth
- CRVL 28.38
- LEGN N/A
- EPS
- CRVL 1.93
- LEGN N/A
- Revenue
- CRVL $918,578,000.00
- LEGN $728,303,000.00
- Revenue This Year
- CRVL N/A
- LEGN $66.76
- Revenue Next Year
- CRVL N/A
- LEGN $52.58
- P/E Ratio
- CRVL $44.83
- LEGN N/A
- Revenue Growth
- CRVL 12.46
- LEGN 112.46
- 52 Week Low
- CRVL $86.14
- LEGN $27.34
- 52 Week High
- CRVL $128.61
- LEGN $59.62
- Technical
- Relative Strength Index (RSI)
- CRVL 28.61
- LEGN 45.74
- Support Level
- CRVL $86.14
- LEGN $38.10
- Resistance Level
- CRVL $89.64
- LEGN $45.30
- Average True Range (ATR)
- CRVL 2.78
- LEGN 1.60
- MACD
- CRVL -0.18
- LEGN -0.74
- Stochastic Oscillator
- CRVL 11.90
- LEGN 4.45
About CRVL CorVel Corp.
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.